Introduction
============

Fat in foods has great palatability and can be addictive to animals \[[@B1],[@B2]\] and human beings \[[@B3]\]. Fats and oils as they exist in nature must be processed before they are suitable for human consumption \[[@B4]\]. Partial hydrogenation of vegetable oils is a common technological aid to food processing with few or no undesirable effects although it can alter the composition of fatty acids. Types of polyunsaturated fatty acids (PUFA) in dietary fats have been shown to profoundly influence lipid metabolism and physiological function. In particular, linoleic acid (18:2, n-6, LA) and α-linolenic acid (18:3, n-3) are metabolized to highly unsaturated fatty acids which have distinct physiological functions \[[@B5]\]. However, epidemiological evidence suggests a strong relationship between the intake of *trans*fatty acids, which are formed during the hydrogenation process, and the risk of coronary heart disease (CHD) \[[@B6]-[@B8]\]. The effect of *trans*fatty acids on the serum lipoprotein profile is at least as unfavorable as that of cholesterol-raising saturated fatty acids, because *trans*fatty acids not only raise low-density lipoprotein (LDL) cholesterol levels but also lower high-density lipoprotein (HDL) cholesterol levels. Later studies, involving either partially hydrogenated fat as the source of *trans*fatty acids or specifically synthesized fat differing in only a single fatty acid, further demonstrate the blood cholesterol raising effects of *trans*fatty acids \[[@B9]-[@B12]\].

In this study, we attempted to synthesize a novel structured lipid using corn oil. LA is the primary (in terms of mass consumed) essential fatty acid in corn oil. It can reduce plasma total cholesterol and LDL-cholesterol \[[@B13],[@B14]\], each of which is an established CHD risk factor. In the present study, the novel structured lipid was produced from corn oil by lipase-catalyzed glycerolysis, which produced a lipid rich in monounsaturated fatty acid (MUFA) and PUFA compared to *trans*fats. This novel structured lipid may provide a beneficial effect on lipid metabolism. Accordingly, we examined the physiological effects of our novel structured lipid on the plasma and hepatic lipid profile in *apo E*^*-/-*^mice, an animal model of atherosclerosis.

Materials and methods
=====================

Test Oil
--------

A commercial shortening (CS, New Orleans, USA) and a low *trans*structured fat from corn oil (LC, Seoul, Korea) were used in this study. 500 g oil blends of anhydrous butterfat (ABF), palm stearin (PS) and corn oil (CO) (8/6/6 and 6/6/9, w/w/w) were added respectively into a 1-L tank stirred-batch type reactor. The tank height and diameter was 11 cm and 15 cm respectively. The enzyme load was 10% of total substrates (50 g, w/w). The reaction was stirred at 230 rpm by an impeller (blade length: 9 cm; blade width: 3.3 cm) and stirrer motor (M Tops MS-3060D, Korea). Lipozyme RM IM and Novozyme 435 were used for blending mixture of 8/6/6 and 6/6/9 by mass (ABF/PS/CO). The reaction for production of the modified-butterfat was carried out for 24 hr in a solvent-free system. Samples were withdrawn during the reaction according to the time course, and then filtered by PTFE syringe membrane filter (25 mm, 0.2 μm, Whatman, USA) to remove the enzyme for analysis. The fatty acid profile was analyzed for each fat used (Table [1](#T1){ref-type="table"}).

###### 

Fatty acid composition of two dietary lipids, a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat, used in animal experiment.

  (unit : %)              
  --------------- ------- -------
  14:00           0.11    0.71
  16:00           13.42   35.81
  16:01           0.07    0.07
  18:00           11.56   15.65
  18:01           12.64   24.07
  18:02           5.39    22.72
  18:03           0.22    0.55
  20:00           0.06    \-
  20:01           0.25    \-
  18:1*T*         43.84   \-
  18:2*T*         11.91   \-
  18:3*T*         0.50    0.42
  Total *Trans*   56.25   0.42
  n-6             5.39    22.72
  n-3             0.22    0.55
  n-6/n-3 ratio   24.50   41.31
  SFA             25.15   52.17
  MUFA            12.71   24.14
  PUFA            5.61    23.27
  P/S             0.22    0.45

SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; P/S, PUFA/SFA ratio.

CS, commercial shortening; LC, low *trans*structured fat from corn oil

Animals and Diets
-----------------

Twenty male apolipoprotein E-deficient (*apo E*^*-/-*^) mice, a well established animal model of atherosclerosis, were imported from Jackson Laboratory (Bar Harbor, Maine, USA) at 5 weeks of age. All the mice were individually housed under a constant temperature (24°C) with 12 h light/12 h dark cycle and fed a palletized commercial chow diet for 1 week after arrival. The mice were then randomly divided into two groups (n = 10) and fed the AIN-76 (American Institute of Nutrition, 1977) basal diet containing 10% (wt/wt) test oil for 12 weeks (Table [2](#T2){ref-type="table"}).

###### 

Composition of experimental diets composed of a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat (unit : % of diet).

  Groups Ingredients   CS    LC
  -------------------- ----- -----
  Casein               20    20
  Methionine           0.3   0.3
  Sucrose              50    50
  Cone starch          10    10
  Fiber                5     5
  Test oils            10    10
  Cholinebitartrate    0.2   0.2
  Mineral mixture^a^   3.5   3.5
  Vitamin mixture^b^   1     1
                             
  Total                100   100

^a^AIN-76 mineral mixture (Harlan Teklad Co., Madison, WI).

^b^AIN-76 vitamin mixture (Harlan Teklad Co.).

CS, commercial shortening; LC, low *trans*structured fat from corn oil

Free access was given to food and water. Blood was taken from a tail vein for the determination of plasma total cholesterol and triglyceride concentration at 0, 3rd, 6th, 9th and 12th wks. Every day for the last 4 days, the feces were collected and analyzed for fecal lipids. The food consumption and body weight were measured daily and weekly. At the end of the experimental period, the mice were anesthetized with ketamine-HCl after food was withheld for 14 hours. Blood samples were taken from the inferior vena cava for plasma lipid analysis. The organs and adipose tissues were removed and rinsed with physiological saline. All samples were stored at -70°C until analysis. This experimental design was approved by the Ethics Committee of Kyungpook National University for the care and use of laboratory animals.

Plasma, hepatic and fecal lipid analysis
----------------------------------------

The plasma triglyceride, total cholesterol and HDL-cholesterol concentrations were enzymatically determined using a commercial kit (Sigma). The plasma apolipoprotein A-I (apo A-I), apolipoprotein B (apo B) and non-esterified fatty acid (NEFA) were also measured using commercial assay kits (Nitto Boseki Co. Ltd, Japan, NEFA-Wako Pure Chemical Industries). The hepatic lipids were extracted using the procedure developed by Folch et al. \[[@B15]\]. The dried lipid residues were dissolved in 1 ml of ethanol for cholesterol and triglyceride assays. Triton X-100 and a sodium cholate solution (in distilled H~2~O) were added to 200 μL of the dissolved lipid solution to produce final concentrations of 5 g/L and 3 mmol/L, respectively. The hepatic cholesterol and triglycerides were analyzed with the same enzymatic kit as used in the plasma analysis.

The feces from each group were collected daily for 1 week and analyzed for lipids, as described previously with a slight modification \[[@B15]\]. Briefly, the feces were dried and extracted in ice-cold chloroform and methanol (2:1, v/v) for 24 h at 4°C. After centrifugation at 900 × *g*for 10 min, the supernatant was collected, dried at 50°C, and dissolved with ethanol. The fecal cholesterol and triglyceride levels were estimated using the same method as used for the liver.

Preparation of hepatic tissue enzyme source
-------------------------------------------

Enzyme source fractions from hepatic tissue were prepared as follows. The tissue 0.5 g was homogenized in a fivefold volume of 0.25 M sucrose buffer and centrifuged at 600 × g for 10 min to remove any cell debris and then the supernatant was centrifuged at 10,000 × g for 20 min to isolate the mitochondrial pellet. Finally, the supernatant was further ultracentrifuged at 105,000 × g for 60 min to obtain the cytosol supernatant. Protein contents in the mitochondrial and cytosolic fractions were measured according to the method of Bradford \[[@B16]\] using bovine serum albumin as the standard.

Hepatic lipid regulating enzyme activities
------------------------------------------

Glucose-6-phosphate dehydrogenase (G6PD) activity was assayed by spectrophotometric methods according to the procedures described by Pitkanen et al. \[[@B17]\], where the activity was expressed as the reduced NADPH (nmol/min/mg protein). The supernatant cytosolic fractions were analyzed for malic enzyme (ME) (EC 1.1.1.40) using modification of the methods of Ochoa \[[@B18]\]. ME activity was expressed as nmol NADPH (nmol/min/mg protein). The hepatic β-oxidation was measured spectrophtometrically by monitoring the reduction of NAD to NADH in the presence of palmitoyl-CoA \[[@B19]\]. The reaction was initiated by addition of the enzyme source to a reaction cuvette containing 20 mM NAD, 0.33 M dithiothreitol, 1.5% bovine serum albumin, 2% Triton X-100, 10 mM CoA, 1 mM FAD, 100 mM KCN, and 5 mM palmitoyl-CoA in 50 mM Tris-HCl (pH 8.0). The reaction compartment was thermostatted at 37°C, and the reaction rate was followed at 340 nm. Data were expressed as nmol of NAD reduced/min/mg of protein. The carnitine palmitoyl transferase (CPT) activity was determined according to the method of Markwell et al. \[[@B20]\]. The results were expressed as nmol/min/mg protein.

3-Hydroxy-3-methylglutaryl (HMG)-CoA reductase and acyl-CoA:cholesterol acyltransferase (ACAT) activities
---------------------------------------------------------------------------------------------------------

The HMG-CoA reductase activity in the microsomal fraction was measured with \[^14^C\]HMG-CoA as the substrate based on a modified method of Shapiro \[[@B21]\], where the activity was expressed as the synthesized mevalonate (pmol/min/mg protein). The ACAT activity in the microsomes was determined by the rate of incorporation of \[^14^C\]oleoyl-CoA into the cholesterol ester fraction, as described by Erickson \[[@B22]\], where the activity was expressed as synthesized cholesteryl oleate (pmol/min/mg protein).

Hepatic Tissue Morphology
-------------------------

Livers were removed and fixed in a buffer solution of 10% formaldehyde. Fixed tissues were processed routinely for paraffin embedding, and 4-μm sections were prepared and dyed with hematoxylin-eosin. Stained areas were viewed using an optical microscope × 100 magnification.

Statistical analysis
--------------------

All data are presented as the mean ± S.E. Statistically significant differences between the groups were determined with a Student\'s *t*test (*p*\< .05) using the standard social science statistical package (SPSS, Chicago, IL, USA).

Results
=======

Food intake, weight gain, FER and organ weights
-----------------------------------------------

Weight gain and food efficiency ratio (FER) were significantly higher in the LC group compared to the CS group, with no change in food intake. The weight of liver and heart (g/100 g body weight) was significantly lower in the LC group than in the CS group (Table [3](#T3){ref-type="table"}).

###### 

Effect of supplementation of a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat on food intake, weight gain, food efficiency ratio (FER) and organ weights in *apo E*^-*/*-^mice.

  Group                          CS            LC
  ------------------------------ ------------- -------------------
   Food Intake (g/day)           4.32 ± 0.09   4.35 ± 0.11
   Weight gain (g/day)           0.12 ± 0.01   0.15 ± 0.01\*\*
   FER                           0.03 ± 0.00   0.03 ± 0.00\*
                                               
  Organ Weights (g/100 g B.W.)                 
   Liver                         6.78 ± 0.29   5.21 ± 0.08\*\*\*
   Heart                         0.46 ± 0.01   0.37 ± 0.02\*\*

Data are mean ± S.E. (*n*= 10).

Values are significantly different from the CS group according to Student\'s *t*test: \**P*\< .05, \*\**P*\< .01, \*\*\**P*\< .001.

FER : Food efficiency ratio = body weight gain/food intake; B.W., Body Weight

CS, commercial shortening; LC, low *trans*structured fat from corn oil

Plasma, hepatic and fecal lipids
--------------------------------

The plasma total cholesterol and triglyceride levels were significantly higher in the LC group (Table [4](#T4){ref-type="table"}). While free fatty acid concentration was unchanged. The HDL-cholesterol, apo A-I, fecal lipids concentrations and the ratio of HDL-cholesterol to total cholesterol were also significantly higher in the LC group compared to the CS group (Table [4](#T4){ref-type="table"}). In addition, hepatic triglyceride, hepatic cholesterol, apo B concentration and atherogenic index, which are all significant risk factors of coronary heart disease, were significantly lower in the LC group (Table [4](#T4){ref-type="table"}).

###### 

Effect of supplementation of a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat on plasma, hepatic and fecal lipid levels in *apo E*^-*/*-^mice.

                                 CS               LC
  ------------------------------ ---------------- --------------------
  Plasma lipids                                   
   Free fatty acid (mmol/L)      1.14 ± 0.03      1.11 ± 0.04
   Triglyceride (mmol/L)         1.46 ± 0.09      2.09 ± 0.08\*\*\*
   Total-C (mmol/L)              16.45 ± 0.81     18.75 ± 0.37\*
   HDL-C (mmol/L)                0.11 ± 0.02      0.81 ± 0.06\*\*\*
   HDL-C/Total-C (%)             0.60 ± 0.06      4.06 ± 0.39\*\*\*
   Atherogenic index^a^          174.95 ± 18.05   23.39 ± 1.99\*\*\*
   Apo A-I (mg/dL)               4.46 ± 0.57      7.47 ± 0.25\*\*\*
   Apo B (mg/dL)                 21.00 ±0.54      17.19 ± 0.60\*\*\*
  Hepatic lipids                                  
   Cholesterol (mmol/g liver)    7.88 ± 0.03      5.83 ± 0.19\*\*\*
   Triglyceride (mmol/g liver)   7.21 ± 0.34      5.27 ± 0.18\*\*
  Fecal lipids                                    
   Cholesterol (μmol/g)          4.60 ± 0.28      6.44 ± 0.37\*\*
   Triglyceride (μmol/g)         2.22 ± 0.54      4.44 ± 0.85\*

Data are mean ± S.E. (n = 10). Values are significantly different from the CS group according to Student\'s *t*test: \**P*\< .05, \*\**P*\< .01, \*\*\**P*\< .001. C:cholesterol.

^a^Atherogenic index: (Total-C-HDL-C)/HDL-C

CS, commercial shortening; LC, low *trans*structured fat from corn oil

Enzyme activities related to fatty acid metabolism in liver
-----------------------------------------------------------

The hepatic and adipocyte G6PD and ME activity were significantly lower in the LC group compared to the CS groups (Table [5](#T5){ref-type="table"}). The activity of hepatic β-oxidation and CPT, the rate-limiting enzyme in fatty acid oxidation, was significantly higher in the LC group compared to the CS group (Table [5](#T5){ref-type="table"}).

###### 

Effect of supplementation of a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat on the enzyme activities related to the hepatic fatty acid metabolism in *apo E*^-*/*-^mice.

                                       CS              LC
  ------------------------------------ --------------- --------------------------
  Fatty acid synthesis                                 
   G6PD (nmol/min/mg protein)          24.90 ± 2.74    7.42 ± 0.30^**\*\*\***^
   ME (nmol/min/mg protein)            217.4 ± 18.64   126.58 ± 15.32^**\*\***^
  Fatty acid oxidation                                 
   β-oxidation (μmol/min/mg protein)   0.43 ± 0.08     5.42 ± 1.13^**\***^
   CPT (nmol/min/mg protein)           19.86 ± 1.42    27.09 ± 1.56^**\*\***^

Data are mean ± S.E. (*n*= 10). Values are significantly different from the CS group according to Student\'s *t*test: \**P*\< .05, \*\**P*\< .01, \*\*\**P*\< .001. G6PD, glucose-6-phosphate dehydrogenase; ME, malic enzyme; CPT, carnitine palmitoyl transferase.

CS, commercial shortening; LC, low *trans*structured fat from corn oil

Hepatic HMG-CoA reductase and ACAT activities
---------------------------------------------

The hepatic ACAT activity was significantly lower in the LC supplemented group than in the CS group, while the hepatic HMG-CoA reductase activity was not significantly between the groups (Figure [1](#F1){ref-type="fig"}).

![**Effect of supplementation of a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat on HMG-CoA reductase (HMGR) and ACAT activities in *apo E***^***-/-***^**mice : CS group (■) and LC group (□)**. The results represent mean ± S.E. (*n*= 10). Values are significantly different from the CS group according to Student\'s *t*test: \**P*\< .05. HMGR, 3-hydroxy-3-methylglutaryl-coenzyme reductase; ACAT, acyl CoA: cholesterol acyltransferase. CS, commercial shortening; LC, low *trans*structured fat from corn oil](1476-511X-10-15-1){#F1}

Morphological changes in hepatocytes
------------------------------------

Lipid droplet accumulation in liver was lower in the LC group compared to the CS group when observed in the light microscope (Figure [2](#F2){ref-type="fig"}). This result was consistent with the hepatic triglyceride and cholesterol profile shown in Table [4](#T4){ref-type="table"}.

![**Effect of supplementation of a hydrogenated *trans*fat and a corn-oil based low *trans*structured fat on hepatic tissue morphology in *apo E*^*-/-*^mice**. The results represent mean ± S.E. (*n*= 10). The results represent mean ± S.E. (*n*= 10). Original magnification × 100. Fat accumulation, indicated by the arrowheads, in the form of large fat droplet is present in liver. CS, commercial shortening; LC, low *trans*structured fat from corn oil](1476-511X-10-15-2){#F2}

Discussion
==========

The present study demonstrates the differential effect of two solid fats, a low *trans*structured fat and a hydrogenated *trans*fat, on plasma and hepatic lipid metabolism in *apo E*^*-/-*^mice. *Trans*fatty acid intake has been convincingly shown to be associated with a significantly higher risk of heart disease based on large epidemiology and clinical studies \[[@B23]-[@B25]\]. Previously in a comprehensive review of past studies summarized *trans*fatty acid intake significantly effects blood lipids, in particular the LDL-cholesterol/HDL-cholesterol ratio and total cholesterol/HDL-cholesterol ratio, leading to increased risk of CHD risk \[[@B26]\]. In the present study, plasma HDL-cholesterol, apo A-I concentrations and HTR were significantly increased, whereas apo B level were significantly lower in the LC group than in the CS group. Apo B and apo A-I are thought to be better predictors of CHD risk than total cholesterol and LDL-cholesterol \[[@B27]\]. Apo A-I also acts as a cofactor for lecithin: cholesterol acyltransferase (LCAT) \[[@B28]\], which is an important enzyme involved in removing excess cholesterol from tissues and incorporating it into HDL for reverse cholesterol transport to the liver \[[@B29]\]. Apo B is synthesized in the liver and is present in LDL, IDL and VLDL particles \[[@B29]\], and therefore the total apo B concentration indicates the amount of potentially atherogenic lipoproteins in plasma or liver \[[@B30]\].

Previous studies have shown that eating partially hydrogenated lipids results in an increase in liver phospholipid concentrations \[[@B31]\]. In the present study, hepatic cholesterol, triglyceride and lipid droplet accumulation in liver was also significantly lowered in the LC group than in the CS group which may contribute reducing liver weight. Hence LC consumption appears to prevent the development of hepatic steatosis in apo E deficient mice. Elevated excretion of cholesterol and triglyceride was also observed in LC fed mice. However, plasma total-C and triglyceride concentration were significantly higher in the LC group than in the CS group. It is plausible that the difference in fatty acid composition between CS and LC could have led to the paradoxical finding of an anti-arterogenic effect in liver but negative pro-arteriogenic effect in blood although at present the mechanism is unclear. A commercial low *trans*fat with high MUFA, myristic acid and palmitic acid content also exhibited the same hepatic lipid-lowering effect but paradosical increase in the plasma cholesterol concentration \[[@B32]\]. Current findings support the dual effects of low *trans*fats, in part, can be modulated by the fatty compositions of these structured fats. Saturated fatty acids (SFAs) are major dietary constituents that can raise plasma total-C concentration \[[@B33]\]. The cholesterol raising properties of SFAs can be primarily attributed to myristic acid (14:0) and palmitic acid (16:0). These SFAs may have different effects on serum total cholesterol concentrations \[[@B34]\]. Replacing SFA with MUFA reduces total cholesterol, LDL-cholesterol, and triglyceride concentrations \[[@B35]\]. Alternatively, the differential effects of low *trans*fat on lowering hepatic lipids in *apo E*^*-/-*^mice can be attributed to their specific fatty acid composition. The CS contains more *trans*fatty acid and less SFA per se in comparison to LC which is rich in linoleic acid, however in MUFA and PUFA vice versa is true and the relative amount of SFA is higher.

Regarding cholesterol metabolism, dietary LC did not significantly lower hepatic HMG-CoA reductase activity, however LC significantly decreased hepatic ACAT activity. HMG-CoA reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway that converts HMG-CoA to mevalonate \[[@B36],[@B37]\]. Intracellular cholesteryl ester (CE) synthesis catalyzed by ACAT serves to store cholesterol in cytosolic droplets and also participates in the hepatic secretion of lipoproteins containing apo B \[[@B38]-[@B40]\]. Moreover, ACAT is believed to be involved in cholesterol absorption from the intestine \[[@B41]\] although this was beyond the scope of the present study. Under pathological conditions, the chronic accumulation of CE produced by ACAT in macrophages and arterial smooth muscle cells leads to the characteristic foam cell formation in atherosclerosis \[[@B42]\]. Therefore, ACAT inhibitors are also expected to be cholesterol-lowering and hence potential anti-atherosclerotic agents.

In summary, an increased hepatic fatty acid synthesis was correlated with the availability of fatty acids for triglyceride synthesis \[[@B43]\]. The activities of two hepatic enzymes G6PD and ME, related to fatty acid synthesis, were lower in the LC supplemented *apo E*^*-/-*^mice in this study. Taken together these findings suggest that the LC supplement had a hepatic triglyceride-lowering effect via lowering the hepatic lipogenic enzyme activities while elevating the hepatic CPT and β-oxidation activity in the *apo E*^*-/-*^mice.

Conclusions
===========

In conclusion, this study provides evidence that low *trans*structured fat from corn oil reduces hepatic lipid accumulation via inhibition of lipogenesis while elevating fatty acid oxidation in *apo E*^*-/-*^mice, a model for atherosclerosis. The differential effects of LC observed on the plasma and liver lipid profile seem to be partly due to the fatty acid composition of LC compared to CS, as LC is high in SFA, MUFA and PUFA content. High SFA in LC may explain the unfavorable effect of LC on plasma triglyceride concentration. We suggest that LC exerts both an anti-atherosclerotic and pro-atherosclerotic effect on plasma and liver lipid metabolism in an atherogenic susceptible animal model. However, further studies are required to verify differential the effects of specific fatty acid composition in low *trans*fats, on lipid metabolism, to justify recommendations to use low *trans*fats such as LC in food processing.
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